Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safe & Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D): Prospective, Multicenter, Double-blind, Randomized Study of Apixaban & Rivaroxaban Removal to Reduce Risk of Serious Bleeding in Urgent Cardiac Surgery Patients

NCT05093504 is registered in ClinicalTrials.gov with CytoSorbents, Inc as lead sponsor.

NCT NCT05093504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05093504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safe & Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D): Prospective, Multicenter, Double-blind, Randomized Study of Apixaban & Rivaroxaban Removal to Reduce Risk of Serious Bleeding in Urgent Cardiac Surgery Patients
Lead sponsor
CytoSorbents, Inc
Phase
Not applicable
Overall status
Terminated
Start date
December 27, 2021
Completion date
January 29, 2024
Enrollment
9 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

blood loss, postoperative, blood loss, surgical, hemorrhage postoperative, hemorrhage, surgical